Crescent Capital Partners - Latest News [Page 1]
Crescent Capital Partners bid for Abano lapses
Tuesday, 18 March 2008, 5:12 pm | Crescent Capital Partners
Auckland, NZ (March 18, 2008): _Crescent Capital Partners has announced acceptances received in its takeover offer for the Abano Healthcare Group, which closed at 5.00pm on Friday March 14, reached 18.510%. In addition, Crescent received a further 1.69% ... More >>
Abano Board advice not in interest of shareholders
Wednesday, 5 March 2008, 5:11 pm | Crescent Capital Partners
Crescent Capital Partners believes Abano’s Board is not acting responsibly in the advice it is providing to shareholders by ignoring market conditions in its latest Earnings Guidance. More >>
Crescent Capital Partners To Waive 90% Condition
Tuesday, 26 February 2008, 4:51 pm | Crescent Capital Partners
Auckland, NZ (February 26, 2008): Crescent Capital Partners (Crescent) today announced that it will waive the 90% condition in its takeover offer for Abano Healthcare Ltd should it receive acceptances taking it over 50%. More >>
Crescent Capital Partners Response To Masthead
Thursday, 17 January 2008, 5:26 pm | Crescent Capital Partners
Auckland, NZ (January 17, 2008): _Following the news that Masthead Portfolios Limited has sold its shareholding of 19.9 percent to Healthcare Industries Limited, Michael Alscher, Executive Director of Crescent Capital Partners, said: More >>
Crescent Capital Partners' Stake In Abano Rises
Monday, 14 January 2008, 10:54 am | Crescent Capital Partners
Auckland, NZ (January 11, 2008): Crescent Capital Partners (Crescent) today announced that it has acquired an additional 8.7 percent of the shares in Abano Healthcare Group Limited (Abano) from some of Abano's largest investors, taking the total number ... More >>
Response to Abano Boards Target Company Statement
Friday, 4 January 2008, 9:59 am | Crescent Capital Partners
Crescent Capital Partners Limited (Crescent) today expressed surprise at the decision taken by the Board of Abano Healthcare Group Limited (Abano) to advise shareholders to reject Crescent’s full cash offer of $5.20 per share, especially given the Crescent ... More >>